{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:30:23Z","timestamp":1778578223618,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,6,27]],"date-time":"2013-06-27T00:00:00Z","timestamp":1372291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The loss of RGCs expressing Thy-1 after optic nerve injury has an initial phase of rapid decline followed by a longer phase with slower reduction rate. This study used longitudinal retinal imaging of mice expressing cyan fluorescent protein under control of the Thy-1 promoter (Thy1-CFP mice) to determine how the \u03b12-adrenergic agonist brimonidine influences loss of Thy1 promoter activation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Baseline images of the fluorescent retinal neurons in 30 Thy1-CFP mice were obtained using a modified confocal scanning laser ophthalmoscope. Next, brimonidine (100 ug\/kg, IP) was administered either one time immediately after optic nerve crush, or immediately after optic nerve crush and then every 2 days for four weeks. A control group received a single saline injection immediately after optic nerve crush. All animals were imaged weekly for four weeks after optic nerve crush. Loss of fluorescent retinal neurons within specific retinal areas was determined by counting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>At one week after optic nerve crush, the proportion of fluorescent retinal neurons retaining fluorescence was 44\u00b17% of baseline in control mice, 51\u00b16% after one brimonidine treatment, and 55\u00b16% after brimonidine treatment every other day (<jats:italic>P<\/jats:italic>&lt;0.05 for both brimonidine treatment groups compared to the control group). Subsequently, the number of fluorescent retinal neurons in the group that received one treatment differed insignificantly from the control group. In contrast, the number of fluorescent retinal neurons in the group that received repeated brimonidine treatments was greater than the control group by 28% at two weeks after crush and by 32% at three weeks after crush (<jats:italic>P<\/jats:italic>&lt;0.05 at both time points). Rate analysis showed that brimonidine slowed the initial rate of fluorescent cell decline in the animals that received multiple treatments (<jats:italic>P<\/jats:italic>&lt;0.05). Differences in the rate of loss among the treatment groups were insignificant after the second week.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Repeated brimonidine treatments protect against loss of fluorescence within fluorescent retinal neurons of Thy1-CFP mice after optic nerve crush. As most of fluorescent retinal neurons in this system are RGCs, these findings indicate that repeated brimonidine treatments may protect RGC health following optic nerve crush.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2415-13-26","type":"journal-article","created":{"date-parts":[[2013,6,27]],"date-time":"2013-06-27T18:14:16Z","timestamp":1372356856000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Brimonidine protects against loss of Thy-1 promoter activation following optic nerve crush"],"prefix":"10.1186","volume":"13","author":[{"given":"Yi","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D","family":"Lindsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen X","family":"Duong-Polk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panida","family":"Chindasub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher Kai-Shun","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert N","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,27]]},"reference":[{"key":"321_CR1","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/S0140-6736(04)16257-0","volume":"363","author":"RN Weinreb","year":"2004","unstructured":"Weinreb RN, Khaw PT: Primary open-angle glaucoma. Lancet. 2004, 363: 1711-1720. 10.1016\/S0140-6736(04)16257-0.","journal-title":"Lancet"},{"issue":"Pt 18","key":"321_CR2","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1113\/jphysiol.2008.156729","volume":"586","author":"AJ Weber","year":"2008","unstructured":"Weber AJ, Harman CD, Viswanathan S: Effects of optic nerve injury, glaucoma, and neuroprotection on the survival, structure, and function of ganglion cells in the mammalian retina. J Physiol. 2008, 586 (Pt 18): 4393-4400.","journal-title":"J Physiol"},{"key":"321_CR3","volume-title":"Prog Retin Eye Res","author":"DJ Calkins","year":"2012","unstructured":"Calkins DJ: Critical pathogenic events underlying progression of neurodegeneration in glaucoma. Prog Retin Eye Res. 2012, Epub ahead of print"},{"key":"321_CR4","first-page":"65","volume":"40","author":"E Yoles","year":"1999","unstructured":"Yoles E, Wheeler LA, Schwartz M: Alpha2 adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci. 1999, 40: 65-73.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"321_CR5","first-page":"2849","volume":"42","author":"E WoldeMussie","year":"2001","unstructured":"WoldeMussie E, Ruiz G, Wijono M, Wheeler LA: Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001, 42: 2849-2855.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"321_CR6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0014-4886(03)00298-X","volume":"184","author":"M Avil\u00e9s-Trigueros","year":"2003","unstructured":"Avil\u00e9s-Trigueros M, Mayor-Torroglosa S, Garc\u00eda-Avil\u00e9s A, et al: Transient ischemia of the retina results in massive degeneration of the retinotectal projection: long-term neuroprotection with brimonidine. Exp Neurol. 2003, 184: 767-777. 10.1016\/S0014-4886(03)00298-X.","journal-title":"Exp Neurol"},{"key":"321_CR7","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1167\/iovs.05-0392","volume":"46","author":"S Mayor-Torroglosa","year":"2005","unstructured":"Mayor-Torroglosa S, De la Villa P, Rodr\u00edguez ME, et al: Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest Ophthalmol Vis Sci. 2005, 46: 3825-3835. 10.1167\/iovs.05-0392.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"321_CR8","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ajo.2008.08.005","volume":"147","author":"K Ma","year":"2009","unstructured":"Ma K, Xu L, Zhang H, Zhang S, Pu M, Jonas J: Effect of brimonidine on retinal ganglion cell survival in an optic nerve crush model. Am J Ophthalmol. 2009, 147: 326-331. 10.1016\/j.ajo.2008.08.005.","journal-title":"Am J Ophthalmol"},{"key":"321_CR9","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/BF01148495","volume":"13","author":"VH Perry","year":"1984","unstructured":"Perry VH, Morris RJ, Raisman G: Is Thy-1 expressed only by ganglion cells and their axons in the retina and optic nerve?. J Neurocytol. 1984, 13: 809-824. 10.1007\/BF01148495.","journal-title":"J Neurocytol"},{"key":"321_CR10","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/biof.41","volume":"35","author":"JE Bradley","year":"2009","unstructured":"Bradley JE, Ramirez G, Hagood JS: Roles and regulation of Thy-1, a context-dependent modulator of cell phenotype. Biofactors. 2009, 35: 258-265. 10.1002\/biof.41.","journal-title":"Biofactors"},{"key":"321_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0304-3940(95)12020-5","volume":"199","author":"S Schmid","year":"1995","unstructured":"Schmid S, Guenther E, Kohler K: Changes in Thy-1 antigen immunoreactivity in the rat retina during pre- and postnatal development. Neurosci Lett. 1995, 199: 91-94. 10.1016\/0304-3940(95)12020-5.","journal-title":"Neurosci Lett"},{"key":"321_CR12","first-page":"1469","volume":"37","author":"CJ Liu","year":"1996","unstructured":"Liu CJ, Chaturvedi N, Barnstable CJ, Dreyer EB: Retinal Thy-1 expression during development. Invest Ophthalmol Vis Sci. 1996, 37: 1469-1473.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"321_CR13","first-page":"192","volume":"7","author":"CL Schlamp","year":"2001","unstructured":"Schlamp CL, Johnson EC, Li Y, Morrison JC, Nickells RW: Changes in Thy1 gene expression associated with damaged retinal ganglion cells. Mol Vis. 2001, 7: 192-201.","journal-title":"Mol Vis"},{"key":"321_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jneumeth.2007.10.018","volume":"168","author":"CK Leung","year":"2008","unstructured":"Leung CK, Lindsey JD, Crowston JG, Ju WK, Liu Q, Bartsch DU, Weinreb RN: In vivo imaging of murine retinal ganglion cells. J Neurosci Methods. 2008, 168: 475-478. 10.1016\/j.jneumeth.2007.10.018.","journal-title":"J Neurosci Methods"},{"key":"321_CR15","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1167\/iovs.07-1447","volume":"49","author":"CK Leung","year":"2008","unstructured":"Leung CK, Lindsey JD, Crowston JG, Lijia C, Chiang S, Weinreb RN: Longitudinal profile of retinal ganglion cell damage after optic nerve crush with blue-light confocal scanning laser ophthalmoscopy. Invest Ophthalmol Vis Sci. 2008, 49: 4898-4902. 10.1167\/iovs.07-1447.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"321_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1167\/iovs.12-10850","volume":"54","author":"P Chindasub","year":"2013","unstructured":"Chindasub P, Lindsey JD, Duong-Polk K, Leung CK, Weinreb RN: Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells. Invest Ophthalmol Vis Sci. 2013, 54: 96-102. 10.1167\/iovs.12-10850.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"321_CR17","first-page":"1559","volume":"14","author":"ID Raymond","year":"2008","unstructured":"Raymond ID, Vila A, Huynh UC, Brecha NC: Cyan fluorescent protein expression in ganglion and amacrine cells in a thy1-CFP transgenic mouse retina. Mol Vis. 2008, 14: 1559-1574.","journal-title":"Mol Vis"},{"key":"321_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1017\/S095252380999023X","volume":"26","author":"ID Raymond","year":"2009","unstructured":"Raymond ID, Pool AL, Vila A, Brecha NC: A Thy1-CFP DBA\/2J mouse line with cyan fluorescent protein expression in retinal ganglion cells. Vis Neurosci. 2009, 26: 453-465. 10.1017\/S095252380999023X.","journal-title":"Vis Neurosci"},{"key":"321_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/exnr.1998.6811","volume":"153","author":"E Yoles","year":"1998","unstructured":"Yoles E, Schwartz M: Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. Exp Neurol. 1998, 153: 1-7. 10.1006\/exnr.1998.6811.","journal-title":"Exp Neurol"},{"key":"321_CR20","doi-asserted-by":"crossref","first-page":"5986","DOI":"10.1523\/JNEUROSCI.16-19-05986.1996","volume":"16","author":"R Wen","year":"1996","unstructured":"Wen R, Cheng T, Li Y, Cao W, Steinberg RH: Alpha2 adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci. 1996, 16: 5986-5992.","journal-title":"J Neurosci"},{"issue":"6","key":"321_CR21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/archopht.120.6.797","volume":"120","author":"H Gao","year":"2002","unstructured":"Gao H, Qiao X, Cantor LB, WuDunn D: Upregulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol. 2002, 120 (6): 797-803. 10.1001\/archopht.120.6.797.","journal-title":"Arch Ophthalmol"},{"key":"321_CR22","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1167\/iovs.06-0890","volume":"48","author":"CJ Dong","year":"2007","unstructured":"Dong CJ, Guo Y, Wheeler L, Hare WA: Alpha2 adrenergic receptor mediated modulation of cytosolic Ca++ signals at the inner plexiform layer of the rat retina. Invest Ophthalmol Vis Sci. 2007, 48: 1410-1415. 10.1167\/iovs.06-0890.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"321_CR23","doi-asserted-by":"publisher","first-page":"e47098","DOI":"10.1371\/journal.pone.0047098","volume":"7","author":"D Lee","year":"2012","unstructured":"Lee D, Kim KY, Noh YH, Chai S, Lindsey JD, Ellisman MH, Weinreb RN, Ju WK: Brimonidine blocks glutamate excitotoxicity-induced oxidative stress and preserves mitochondrial transcription factor a in ischemic retinal injury. PLoS One. 2012, 7: e47098-10.1371\/journal.pone.0047098.","journal-title":"PLoS One"},{"key":"321_CR24","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1167\/iovs.08-2078","volume":"49","author":"CJ Dong","year":"2008","unstructured":"Dong CJ, Guo Y, Agey P, Wheeler L, Hare W: Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci. 2008, 49: 4515-4522. 10.1167\/iovs.08-2078.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"321_CR25","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archopht.1997.01100160201010","volume":"115","author":"LA Kerrigan","year":"1997","unstructured":"Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME: TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997, 115: 1031-1035. 10.1001\/archopht.1997.01100160201010.","journal-title":"Arch Ophthalmol"},{"key":"321_CR26","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/01.ijg.0000169411.09258.f6","volume":"14","author":"JD Lindsey","year":"2005","unstructured":"Lindsey JD, Weinreb RN: Elevated intraocular pressure and transgenic applications in the mouse. J Glaucoma. 2005, 14: 318-320. 10.1097\/01.ijg.0000169411.09258.f6.","journal-title":"J Glaucoma"},{"key":"321_CR27","first-page":"1370","volume":"41","author":"AJ Weber","year":"2000","unstructured":"Weber AJ, Chen H, Hubbard WC, Kaufman PL: Experimental glaucoma and cell size, density, and number in the primate lateral geniculate nucleus. Invest Ophthalmol Vis Sci. 2000, 41: 1370-1379.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"321_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0079-6123(08)01132-1","volume":"173","author":"Y Y\u00fccel","year":"2008","unstructured":"Y\u00fccel Y, Gupta N: Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration. Prog Brain Res. 2008, 173: 465-478.","journal-title":"Prog Brain Res"},{"key":"321_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.visres.2012.03.012","volume":"60","author":"RO Duncan","year":"2012","unstructured":"Duncan RO, Sample PA, Bowd C, Weinreb RN, Zangwill LM: Arterial spin labeling fMRI measurements of decreased blood flow in primary visual cortex correlates with decreased visual function in human glaucoma. Vision Res. 2012, 60: 51-60.","journal-title":"Vision Res"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-13-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2415-13-26\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-13-26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2415-13-26.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:24:46Z","timestamp":1630542286000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/1471-2415-13-26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,27]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1186\/1471-2415-13-26","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,27]]},"assertion":[{"value":"30 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"26"}}